Loading…
← CockpitCompetitor Analysis › PRCT PROCEPT BioRobotics Corp.Open in the cockpit ↗

PROCEPT BioRobotics Corp.PRCTCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 86
Mkt cap
$1.45B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$30.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-59.1 pp
WACC 9.2%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$25.18
1D+5.9%
1W+7.9%
1M+33.8%
3M+21.5%
6M-10.4%
YTD-20.0%
1Y-13.4%
ATR %5.4%
Beta1.07
52w lowhigh33.9% off high

What PROCEPT BioRobotics does

Employees: 888

PROCEPT BioRobotics at a glance

Size PROCEPT BioRobotics (PRCT) is a United States Health Care company (Medical Specialties) with a market value of $1.45B, the 1992nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.18 on 18 Nov 2026.

Performance Over six months the shares fell 10.4%, against -7.0% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 17.5% over the last twelve months (peer median +10.8%); the operating margin is -33.6% (peer median 8.2%).

Valuation It trades at 3.7× enterprise value to sales against a peer median of 3.1× (9th most expensive of 21).

Capital Return on invested capital runs 59.1 points below its cost of capital (9.2% WACC).

Short interest Short interest is 13.7% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 95PRCT 87
Six months, rebased to 100: PROCEPT BioRobotics against the median of its 20 peers (local-currency closes).

PROCEPT BioRobotics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$352M$308M$224M$136M$75.0M
Revenue growth—+37%+65%+82%—
Gross profit$228M$196M$137M$71.0M$37.1M
EBITDA-$110M-$97.5M-$91.4M-$105M-$76.4M
Net income-$115M-$95.6M-$91.4M-$106M-$87.2M
Free cash flow-$85.1M-$58.3M-$104M-$133M-$83.0M
Capital expenditure$8.38M$9.36M$4.41M$25.2M$2.65M
Total debt$77.0M$78.5M$80.2M$79.2M$77.3M

Quarterly statements and history in the cockpit →

PROCEPT BioRobotics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%300298300049ELNCNMD6880166849ENOVVITR6885313005953010876881986887583006336699BFLYSTAANVCR8086INSPPRCT6-month return →1-month return →
Up and to the right = strong over both horizons. PROCEPT BioRobotics is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%5×10×300298300049ELNCNMD6880166849VITR6885313005953010876881986887583006336699BFLYSTAANVCRPRCTRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PROCEPT BioRobotics is the large dot.

PROCEPT BioRobotics competitors and peer comparison

How PROCEPT BioRobotics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PROCEPT BioRobotics against its 20 peers (data as of 18 Nov 2026)
MeasurePRCTPeer medianRank in peer set
1-month return+33.8%-1.6%highest of 21
6-month return-10.4%-7.0%9th lowest of 21
Distance from 52-week high-33.9%-28.4%9th lowest of 21
Revenue growth (TTM)+17.5%+10.8%8th highest of 21
Operating margin-33.6%8.2%2nd lowest of 21
EV / Sales3.7×3.1×9th most expensive of 21
ROIC minus cost of capital-59.1 pp+0.5 pp3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%3.7×n/an/a
Sinocare 300298.SZChina$1.45B+4%+7%6%2.0×9.5%+18.3%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%6.0×2.9%+14.6%
El.En ELN.MIItaly$1.46B+11%+3%15%2.1×10.7%+7.7%
CONMED CNMDUnited States$1.43B+30%+2%2%1.6×31.6%+9.8%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%5.7×2.7%+23.4%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%0.9×-3.5%+3.3%
Enovis ENOVUnited States$1.56B+2%+3%4%1.3×20.0%-6.0%
Vitrolife VITR.STSweden$1.57B+13%-2%19%4.9×22.2%+22.5%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%6.9×n/an/a
Ovctek China 300595.SZChina$1.33B-25%0%28%3.8×8.3%+16.5%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%2.1×11.2%+7.4%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%13.4×20.7%+27.6%
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%15.4×22.8%+23.6%
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%3.3×n/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%3.0×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%12.3×n/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%3.4×35.1%+7.9%
NovoCure NVCRUnited States$1.25B-40%+13%-17%1.4×n/an/a
NIPRO 8086.TJapan$1.68B-11%+5%5%1.3×n/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%1.6×28.7%+51.2%

Questions

Which companies are PROCEPT BioRobotics's closest peers?
The cockpit's peer set: Sinocare (300298.SZ), Inner Mongolia Furui Medical Science (300049.SZ), El.En (ELN.MI), CONMED (CNMD), Shanghai MicroPort Endovascular MedTech (688016.SS), Nihon Kohden (6849.T), Enovis (ENOV), Vitrolife (VITR.ST).
Is PROCEPT BioRobotics expensive compared with its peers?
On ev / sales it trades at 3.7× against a peer median of 3.1×, 9th most expensive of 21 in its peer set.
How has PROCEPT BioRobotics stock performed?
Over six months to 18 Nov 2026 the shares returned -10.4% against -7.0% for the median peer; over one year -13.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.